LI-RADS Grading and Management
For hepatic lesions in at-risk patients, LI-RADS provides a standardized categorization system (LR-1 through LR-5, plus LR-M and LR-TIV) with specific management pathways based on malignancy probability, where LR-5 lesions are treated as definite HCC without biopsy, while lower categories require surveillance or further diagnostic workup. 1
LI-RADS Categories and Their Meanings
The LI-RADS system stratifies liver observations according to HCC probability 2:
- LR-1 (Definitely Benign): No malignancy risk 2
- LR-2 (Probably Benign): HCC in 2-18% of cases 1
- LR-3 (Intermediate Probability): HCC in 32-60% of cases, overall malignancy in 38-40% 1, 3
- LR-4 (Probably HCC): HCC in 67-93% of cases, overall malignancy in 74-80% 1, 3
- LR-5 (Definitely HCC): 97% confirmed as HCC 1
- LR-M (Malignancy, Not HCC-Specific): Indicates probable malignancy such as intrahepatic cholangiocarcinoma 1
- LR-TIV (Tumor in Vein): Macrovascular invasion 1
Management by LI-RADS Category
LR-5 (Definitely HCC)
Proceed directly to HCC staging and treatment without biopsy. 4, 1 The LR-5 category has excellent specificity (97%) and can be diagnosed non-invasively using multiphasic CT or dynamic contrast-enhanced MRI 1. Key imaging features include:
- Non-rim arterial phase hyperenhancement (APHE) 1
- Late (>60 seconds) and mild washout 1, 2
- Size ≥10 mm with additional major features (enhancing capsule, nonperipheral washout, or threshold growth) 2
Complete staging requires chest CT to evaluate for metastatic disease before considering liver transplantation 4.
LR-4 (Probably HCC)
Obtain follow-up imaging within 3 months OR perform biopsy, with treatment decisions made through multidisciplinary discussion. 3 During surveillance, 20-34% of LR-4 lesions progress to LR-5 within 3 months, and 37-75% progress within 6 months 3.
For lesions with APHE but lacking washout, ancillary features can support the LR-4 designation, including 3:
- Enhancing or non-enhancing capsule
- Mosaic architecture
- Nodule-in-nodule appearance
- Mild-to-moderate T2 hyperintensity
- Restricted diffusion
- Threshold growth
LR-3 (Indeterminate)
Perform follow-up imaging within 6 months OR consider biopsy based on clinical risk factors. 3 The risk stratification should account for 3:
- Patient age
- Presence of APHE
- Nodule size (>1 cm carries higher risk)
- Serum albumin ≤3.5 g/dL
- AFP ≥100 ng/mL
During follow-up, 0-25.8% of LR-3 lesions progress to LR-5 within 6 months, and 8.9-57.3% progress within 6-12 months 3. Extended surveillance up to 2 years may be appropriate given HCC doubling time 3.
LR-2 (Probably Benign)
Continue routine surveillance imaging every 6 months. 2 While the HCC risk is low (2-18%), these patients remain at risk and require ongoing monitoring 1.
LR-1 (Definitely Benign)
Return to standard surveillance protocol without additional imaging. 2
LR-M (Probable Malignancy, Not HCC-Specific)
Biopsy is mandatory for definitive diagnosis. 1 These lesions show features suggesting malignancy but not typical for HCC, such as rim APHE, early (<60 seconds) washout, or marked washout 2. This category helps identify intrahepatic cholangiocarcinoma and other non-HCC malignancies 1.
LR-TIV (Tumor in Vein)
Treat as advanced HCC with macrovascular invasion. 1 These patients typically require systemic therapy rather than locoregional treatment 4.
Diagnostic Imaging Modalities
Multiphasic CT or dynamic contrast-enhanced MRI are the preferred diagnostic modalities, with equivalent performance and no preference between them. 1 Both achieve sensitivity of 89% and specificity of 96% for HCC diagnosis 4.
Contrast-Enhanced Ultrasound (CEUS)
CEUS can be used for HCC diagnosis with specific criteria 2:
- APHE followed by late (>60 seconds) and mild washout indicates LR-5 2
- Limited to characterizing 1-2 targeted lesions per examination 2
- Not suitable for complete staging due to incomplete liver visualization 2
- Sensitivity of 46% for 1-2 cm HCC (lower than CT/MRI at 70-71%) 1
Lesions <1 cm
For subcentimeter nodules detected during surveillance, perform follow-up ultrasound within 3-6 months. 4, 5 LI-RADS requires lesions ≥10 mm for definitive HCC diagnosis 5. The small size makes characterization on cross-sectional imaging difficult, and the risk of malignancy is lower 4.
When Biopsy is Required
Biopsy is indicated when 1:
- Imaging criteria for definite or probable HCC are not met
- LR-M category is assigned
- Clinical suspicion remains high despite negative imaging
Biopsy technique should include 1:
- Percutaneous access under CT or ultrasound guidance
- Sufficient tissue sampling with adequate needle size
- Serial sections with H&E and reticulin staining
- Additional immunostaining when differentiating dysplastic nodules from early HCC
Important caveats: Biopsy has variable sensitivity (66-93%) depending on tumor size, operator experience, and needle size, with excellent specificity (100%) 1. Risks include track seeding (1-3%) and bleeding 6. Avoid biopsy of potentially resectable lesions when possible 6.
Common Pitfalls
- Do not use single-phase CT or non-contrast imaging for LI-RADS categorization – multiphase imaging is essential for detecting arterial hyperenhancement and washout 4
- Recognize that LR-3 and LR-4 categories have overlapping HCC probabilities – the wide ranges (32-60% for LR-3,67-93% for LR-4) necessitate individualized follow-up strategies 1
- CEUS has lower sensitivity than CT/MRI for small HCC (1-2 cm) – 26-46% versus 68-71% 1
- Perilesional enhancement after treatment represents reactive changes, not viable tumor – especially within the first 3 months post-treatment 7